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Abstract 
Background: To determine the prevalence of xerostomia and hyposalivation in Haemodialysis (HD) patients, 
to clarify risk factors, assess patient s´ quality of life, and to establish a possible correlation among interdialytic 
weight gain (IDWG) and xerostomia. 
Material and Methods: This study was performed on a group of 50 HD patients. Data were collected using a ques-
tionnaire containing demographic and clinical variables, a visual analogue scale (VAS) for xerostomia, IDWG, 
and an oral health impact profile questionnaire (OHIP-14). Unstimulated whole saliva (UWS) and stimulated 
whole saliva (SWS) were collected. 
Results: A total of 28 HD patients (56%) suffered xerostomia. Dry mouth was associated with hypertension (OR, 
5.24; 95% CI, 1.11-24.89) and benzodiazepine consumption (OR, 5.96; 95% CI, 1.05-33.99). The mean xerostomia 
VAS and OHIP-14 scores were 31.74±14.88 and 24.38±11.98, respectively. No significant correlation was observed 
between IDWG% and VAS and OHIP total score. Nonetheless, a positive correlation between VAS level of thirst 
and IDWG% was found (r=0.48 p=0.0001). UWS and SWS means (determined in 30 patients) were 0.16±0.17 
and 1.12±0.64, respectively. Decreased values of UWS and SWS were reported in 53.33% and 36.66% of HD 
patients. 
Conclusions: Xerostomia in HD has a multifactorial aetiology due to accumulative risks as advanced age, sys-
temic disorders, drugs, fluid intake restriction, and salivary parenchymal fibrosis and atrophy. Therefore, it is 
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important to detect possible xerostomia risk factors to treat correctly dry mouth in HD patients and avoid systemic 
complications.
Key words: Haemodialysis patients, xerostomia, salivary flow rate, hyposalivation, interdialytic weight gain, oral 
health-related quality of life.
Introduction
End-stage renal disease (ESRD) is the last stage for 
several primary kidney diseases, and systemic diseases 
with renal involvement, causing kidney function loss. 
The most common reasons of ESRD are diabetic ne-
phropathy, chronic glomerulonephritis, interstitial ne-
phritis, hypertension or vascular disease, hereditary or 
congenital disease and neoplasms (1). 
ESRD incidence is increasing, the number of patients 
being treated for ESRD globally was estimated at 
2,786,000 at the end of 2011 and, with a 6-7% growth 
rate continues to increase at a significantly higher rate 
than that of the world population. Of these ESRD pa-
tients, approximately 1,929,000 were undergoing hae-
modialysis (HD) treatment (2).
Oral lesions may be observed in HD patients. The most 
frequent oral disorders observed are xerostomia, hy-
posalivation, adverse effects related to drug therapy, 
mucosal lesions as petechiae, gingival hyperplasia, oral 
infections, dental anomalies and bone lesions (1,3,4). 
Xerostomia is a subjective complaint of dry mouth, 
whereas hyposalivation is an objective decreased of 
salivary flow. Many cases of xerostomia have been 
described in patients with a normal salivary flow rate 
(5,6). Previous studies have shown that the percentage 
of HD patients who suffer from xerostomia is higher 
and ranges between 32 and 81% (4,7-13). 
In patients undergoing HD, xerostomia is associated 
with the following problems: difficulties in chewing, 
swallowing, tasting and speaking (6,14); increased risk 
of oral diseases, including lesions of mucosa, gingiva 
and tongue; bacterial and fungal infections, such as 
candidiasis, dental caries and periodontal disease; inter-
dialytic weight gain (IDWG) resulting from increased 
fluid intake; and a reduction in quality of life (14).
Xerostomia in HD patients is caused for many factors 
such as fluid intake restriction, old age, reduced sali-
vary flow, minor salivary glands parenchymal fibro-
sis and atrophy, mouth breathing and medication use 
(9,10,12,14,15). Drugs with xerostomizing effects are 
anticholinergic, sympathomimetic, antihypertensive, 
cytotoxic, anti-HIV drugs, opiods and benzodiazepines, 
as well as, anti-migraine agents (6,16). Some psycholog-
ical factors, such as stress, anxiety or depressive condi-
tions are also related to xerostomia (16,17).
IDWG is a measurable parameter used in the dialysis 
service to make decisions regarding the amount of fluid 
removal during a dialysis session. HD patients have to 
maintain a correct fluid volume balance, which should 
be achieved by daily restrictions in fluid consumption. 
Improper drinking behaviours in HD patients lead to 
fluid overload, which may give rise to hypertension, 
pulmonary oedema or other cardiovascular manifesta-
tions (11,18). 
Previous studies have found an important number of 
HD patients suffered from thirst, xerostomia and saliva 
reduction (15,18). Likewise, some studies have observed 
the existence of a positive correlation among thirst, 
xerostomia and IDWG in HD patients  (11,14,18,19). 
These factors could contribute on morbidity and mor-
tality of HD patients. 
The aim of this study is to determine the prevalence 
of xerostomia and hyposalivation in a group of HD 
patients, to clarify the risk factors associated to xeros-
tomia in these patients, and to assess patient s´ quality 
or life. The study also tries to establish a connection 
among IDWG, xerostomia and hyposalivation in HD 
patients. 
Material and Methods
- Patients
The study was conducted in compliance with the prin-
ciples of the Declaration of Helsinki. An ethics commit-
tee at Hospital San Carlos, Madrid, Spain, approved the 
study protocol. We obtained a written informed consent 
from each of the participants prior to his/her inclusion 
in the study. Patients were included in the study from 
May 2015 to March 2016. We used the following inclu-
sion criteria with the participants: ≥1 month on HD, 18 
years of age or older, mentally and physical ability to 
participate and complete the study. Patients with he-
modynamic instability, therefore preventing them from 
ultrafiltration, being hospitalized 2-months prior to the 
study, dementia or terminal diseases, logistic impossi-
bility of investigation, taking any medication or prod-
uct for his/her dry mouth condition, and/or unwilling to 
participate in the study were excluded. 
We included fifty HD patients in our study and ob-
served them in a haemodialysis clinic, Asyter, in Alcá-
zar de San Juan, Spain. All patients received a fixed HD 
schedule of 3 times per week. Age, gender, causes of 
ESRD, underlying diseases, consumed drugs, presence 
of dentures, tobacco, alcohol, time on HD, dry weight, 
and body mass index were recorded.
- IDWG Assessment
Each participant was weighed before and after each di-
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alysis session for 2 weeks (6 sessions). IDWG being the 
amount of fluid (kg) removed during the dialysis ses-
sion. Dividing IDWG mean of 6 sessions by the patient s´ 
target dry weight and multiplying this result per 100 
obtained IDWG%. The target dry weight of the patient 
was determined according to the standard clinical crite-
ria by nephrologists. 
- Xerostomia
The patients that replied positively to the question: “are 
you normally aware of your dry mouth?,” were consid-
ered to have xerostomia (17). 
- Xerostomia visual analogue scale (VAS) question-
naire
The patients were questioned about their sensation of 
dry mouth, and then asked to use a validated VAS ques-
tionnaire that contained eight items addressing oral 
dryness (20). VAS questionnaire was assessed before 
dialysis session. Subjects were asked to draw a vertical 
line through a horizontal line, 10 cm long, to indicate 
their level of dryness for each of the items. 
- Assessment of Oral Health Impact Profile (OHIP)-14
The Spanish validated version of the OHIP-14 question-
naire was done to assess patient quality of life (21). It 
consists of 14 items that assess different aspects of oral 
function and quality of life. Feedback is based on a Lik-
ert format, with a five-point ordinal scale ranging from 
“never” (coded 1) to “very often” (coded 5). The score 
ranges from 0 to 70, where higher scores correspond to 
poorer oral quality of life. The questionnaire was done 
before dialysis session.
- Saliva collection
Unstimulated whole saliva (UWS) and paraffin chewing-
stimulated whole saliva (SWS) were collected before 
HD session at 8 am. A trained investigator (RMLP), 
blind to all clinical data and xerostomia and OHIP-14 
questionnaires results, collected the saliva. UWS and 
SWS were only determined in patients that received 
HD treatment in the morning (30 patients). All subjects 
were given instructions to not smoke, eat, drink or too-
th brush at least 90 minutes prior to saliva collection. 
UWS and SWS were collected for 15 min using an esta-
blished spitting technique. The patients were seated in 
an upright position, and asked to relax during spitting. 
Saliva volume was determined in millimetres per minu-
te (mL/min). Hyposalivation was present when salivary 
flow rate was <0.1 mL/min at rest or <0.7 mL/min under 
stimulation (5,6). 
- Statistical analysis
The statistical analysis comprised basic descriptive sta-
tistics. The normality of the distribution was checked 
with the Kolmogrov-Smirnov test. Differences between 
continuous and categorical variables were assessed by a 
Student t test, and the chi-square test or Fisher’s exact 
test, respectively. To explore the association between 
xerostomia and selected clinical variables, a multiple 
logistic regression model was fitted. Variables stayed 
in the model if they were predictors of the outcome (P 
< 0.05). The final model included hypertension, alpha-
adrenergic blockers antihypertensives, and benzodi-
azepines. Pearson s´ correlation coefficient was used to 
assess the correlations between continuous variables. 
All statistical analyses were conducted using the statis-
tical software SPSS 22.0. Differences were considered 
significant if p was less than 0.05. 
Results
Fifty HD patients (35 men and 15 women) were enrolled 
in this study. The mean age was 66.62±13.96, and these 
patients were on HD for 46.02±44.90 months. The clini-
cal characteristics were presented in table 1. Twenty-
eight patients (56%) were reported to suffer xerostomia. 
Xerostomia cases showed no significant differences with 
regard to gender distribution, age, time on HD, causes 
of ESRD, number of consumed drugs, diabetes, body 
mass index, dry weight, IDWG average, alcohol and to-
bacco consumption, and denture presence. Among the 
xerostomia cases, there were significantly more HD pa-
tients with hypertension. 
Drugs with potential to cause salivary dysfunctions 
consumed by HD patients of this study were presented 
in table 2. We found statistical correlation between the 
consumption of alpha-adrenergic blockers antihyper-
tensives and benzodiazepines, and xerostomia sensa-
tion.
The final multiple logistic regression model showed 
odds ratios (ORs) and 95% confidence intervals (CIs). 
The model showed that xerostomia in HD patients was 
significantly associated with hypertension (OR, 5.24; 
95% CI, 1.11-24.89; p=0.03) and benzodiazepine con-
sumption (OR, 5.96; 95% CI, 1.05-33.99; p=0.04). Nev-
ertheless, xerostomia was not significantly associated 
with Alpha Adrenergic blockers antihypertensives con-
sumption (OR, 4.26; 95% CI, 0.94-19.28; p=0.06). 
The mean VAS score of the study population was 
31.74±14.88 (Table 3), the item 3 (lack of saliva in 
mouth) and the item 8 (level of thirst) obtained the high-
est values with 5.45±2.47 vs 5.77±2.78.
The results of OHIP-14 scores are presented on table 4. 
The mean total score was 24.38±11.98. A positive cor-
relation between xerostomia VAS score and OHIP-14 
score was observed in HD patients (r=0.78, p=0.0001).
We observed that xerostomia HD patients obtained high-
er VAS and OHIP-14 scores. The mean total VAS score 
was 38.30±15.07 in xerostomia patients vs. 23.37±9.69 
(p=0.0001). Mean OHIP-14 scores was 29.64±13.65 in 
HD patients with xerostomia and 17.68±3.40 in non-
xerostomia patients (p=0.0001).
No significant correlation was observed between 
IDWG% and VAS total score (r=0.17 p=0.23). Nonethe-
less, a positive correlation between VAS level of thirst 
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and IDWG% was found (r=0.48 p=0.0001). No corre-
lation was noted between OHIP-14 questionnaire and 
IDWG% (r=0.004 p=0.98).
UWS and SWS were only determined in 30 patients that 
received HD treatment in the morning. The mean UWS 
and SWS were 0.16±0.17 and 1.12±0.64, respectively. 
Abnormal values of UWS (<0.1 mL/min) were reported 
in 16 patients (53.33%). Eleven HD patients (36.66%) 
had abnormal levels of SWS (<0.7 mL/min).
Of 30 patients, 57.1% of HD with UWS <0.1 mL/min 
and 33.3% of HD with SWS <0.7 mL/min had xerosto-
mia (p=0.69 vs. p=0.68). We did not find a relationship 
between the volume of UWS and SWS, and xerostomia 
(p=0.51 vs. p=0.53).
Negative correlations were found between UWS (r=-
0,25, p=0.18) and SWS (r=-0.14, p=0.46) and the total 
OHIP-14 score, patients with higher OHIP-14 levels had 
lower volumes of saliva, but these correlations were not 
significant. Nevertheless, a significant negative correla-
tion was found between UWS and VAS score (r=-0.46, 
p=0.01), patients with higher VAS score had lower vol-
ume of saliva. No significant correlation between SWS 
and VAS score (r=-0.30, p=0.11) was observed.
Discussion
The prevalence of xerostomia varies from 6 to 30% 
in older European adult population (11,14). Previous 
studies found that xerostomia was the most common 
oral disorder in HD patients (22), and showed that per-
centage of HD patients who suffer from xerostomia is 
higher, and ranges between 32 and 81% (4,8-13,19). The 
results of this study show a xerostomia prevalence of 
56% in HD patients, our results are in accordance with 
the range prevalence found previously in HD patients, 
and it is higher than prevalence found in general older 
population. 
It is known that main factors associated with xerostomia 
are ageing, head and neck radiotherapy, systemic disor-
ders, and several drugs. Systemic diseases associated to 
xerostomia are rheumatological chronic inflammatory 
Variables n (%) or mean±SD p
Gender
Male
Female
35 (70%)
15 (30%)
0.37 (b)
Age 66.62±13.96 0.30 (c)
Time on HD (months) 46.02±44.90 0.56 (c)
Causes of ESRD
Chronic glomerulonephritis
Polycystic kidney disease
Diabetic nephropathy
Hypertension
Others
11 (22%)
5 (10%)
16 (32%)
8 (16%)
10 (20%)
0.83 (a)
Number of consumed drugs 8.38±3.70 0.72 (c)
Diabetes
Type 1
Type 2
2 (4%)
16 (32%)
0.98 (a)
Hypertension 34 (68%) 0.01 (a)
Body mass index 28.70±4.84 0.15 (c)
Dry weight 76.50±15.91 0.34 (c)
IDWG average (kg) 2.05±0.73 0.86 (c)
IDWG average (%) 2.78±1.14 0.47 (c)
Smokers 6 (12%) 0.99 (b)
Alcohol 7 (14%) 0.11 (a)
Dentures 17 (34%) 0.77 (a)
Table 1. Characteristics of the HD patients and relationship between variables and 
xerostomia.
Values are number (%) and mean ± standard deviation (SD). Statistical tests: (a) chi-
square test, (b) Fisher test, (c) Student t test. ESRD=end-stage renal disease.
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disorders (Sjögren syndrome, rheumatoid arthritis, sys-
temic lupus erythematosus), endocrine disorders (dia-
betes mellitus, hyperthyroidism and hypothyroidism), 
neurologic disorders (depression and Parkinson s´ dis-
ease), genetic disorders, metabolic disorders (dehydra-
tion, anaemia and alcohol abuse), infectious disorders 
(HIV/AIDS, HCV infection), and others (fibromyalgia, 
sarcoidosis and chronic pancreatitis) (6,23). A lot of cas-
es of xerostomia are related to psychological conditions 
like depression and anxiety (16,17). 
Different papers have studied the effects of ageing on 
salivary production, but there is still controversy with 
regards to salivary dysfunctions in the elderly. There 
are studies that have demonstrated impaired glandular 
function, and others have not found salivary dysfunc-
Drugs n (%) p
Anticholinergic drugs
Antipsychotics
Antihistamines
Anticholinergic Bronchodilators
7 (14%)
1 (2%)
1 (2%)
0.37
0.37
0.37
Sympathomimetic drugs
Antidepressant
Decongestants
b2-Agonists Bronchodilators 
8 (16%)
2 (4%)
4 (8%)
0.71
0.20
0.42
Antihypertensive
Angiotensin converting enzyme inhibi-
tors 
Angiotensin II receptor antagonists
Calcium channel blockers
Alpha Adrenergic blockers
Beta Adrenergic blockers
Diuretics
6 (12%)
11 (22%)
15 (30%)
13 (26%)
6 (12%)
19 (38%)
0.75
0.14
0.38
0.03
0.23
0.83
Cytotoxic drugs
Antineoplastics 1 (2%) 0.37
Benzodiazepines 10 (20%) 0.05
Table 2. Drugs with potential to cause salivary dysfunctions consumed by HD patients 
and their relationship with xerostomia.
Values are number (%). The statistical test used was chi-square test.
VAS (cm) Score (mean±SD)
VAS speech difficulties 3.15±3.44
VAS swallowing difficulties 2.34±3.25
VAS lack of saliva in mouth 5.45±2.47
VAS dry mouth sensation 4.49±3.23
VAS dry throat sensation 2.76±2.99
VAS dry lip sensation 4.38±2.96
VAS dry tongue sensation 3.39±3.12
VAS level of thirst 5.77±2.78
VAS Total 31.74±14.88
OHIP-14 Score (mean±SD)
Functional limitation
Question 1
Question 2
4.20±2.45
2.26±1.45
1.94±1.38
Physical pain
Question 3
Question 4
4.04±2.13
2.08±1.31
1.96±1.32
Psychological discomfort
Question 5 
Question 6
3.98±2.54
2.16±1.46
1.82±1.30
Physical disability
Question 7
Question 8
3.34±2.05
1.80±1.31
1.54±1.01
Psychological disability
Question 9
Question 10
3.26±1.94
1.74±1.24
1.52±1.15
Social disability
Question 11
Question 12
2.76±1.68
1.48±1.09
1.28±0.73
Handicap
Question 13
Question 14
2.80±1.84
1.54±1.18
1.26±0.80
Total OHIP-14 24.38±11.98
Table 3. VAS questionnaire scores.
Table 4. OHIP-14 scores.
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tions among healthy, non-drug consuming, aging popu-
lation (6,23). In HD patients, there are studies that have 
shown that dry mouth is associated with age (18,19,24). 
Nevertheless, we have not found a relationship between 
age and xerostomia in our patients.
Most HD patients have complex medical conditions, 
including hypertension and diabetes, and a lot of HD 
patients take many medications that increase the risk of 
xerostomia (4). In this study, we recorded the systemic 
diseases suffered by each HD patient, and observed a 
relationship between hypertension and xerostomia. It is 
difficult to clarify if xerostomia is associated with high 
blood pressure or to hypertension treatment that is re-
lated to dry mouth, as we can see below. 
It is not clear if diabetic HD patients have higher xeros-
tomia prevalence. Diabetes mellitus and disturbances 
in glycaemic control could damage the gland s´ paren-
chyma, and cause alterations in the micro-circulation of 
the salivary glands as dehydration (6). There are studies 
that have shown that xerostomia was severe in diabetic 
compared with non-diabetic HD patients, and HD pa-
tients with poor glycemic control also showed higher 
xerostomia incidence (25). In addition, there are studies 
that observed that HD patients that begin HD due to di-
abetic nephropathy have greater xerostomia than those 
that begin due to glomerulonephritis (1). Although, au-
thors like Swapna et al. (13) did not observe a significant 
relationship between xerostomia and diabetes among 
HD patients. We, as well, have not found a relationship 
between diabetes and xerostomia but we think that it is 
necessary further research to clarify a possible influ-
ence of diabetes on dry mouth in HD patients reflecting 
also their glycaemic levels. 
As we described earlier, there are lots of drugs with 
potential to cause salivary dysfunction. Unfortu-
nately, little data about the effects of many supposed 
xerostomia-inducing drugs on salivation are available 
(6). According to some authors, xerostomia prevalence 
rises with increasing numbers of drugs used (23,26). In 
the present study, it was observed that the number of 
consumed drugs did not increase the risk of suffering 
xerostomia. Although, we found that among the differ-
ent drug categories associated with xerostomia taken by 
HD patients, only alpha-adrenergic blockers and benzo-
diazepines were associated with dry mouth.
Dry mouth has been related as a side effect of differ-
ent kinds of drugs for antihypertensive therapies, which 
produce salivary dysfunction in different ways (6,16). 
Diuretics cause an overall decrease in intravascular and 
extracellular fluid volume and, as a consequence, de-
crease salivary flow rate (6). Anti-hypertensives that act 
in alpha-2-adrenergic receptors frequently cause xeros-
tomia. There are authors that have demonstrated that 
alpha 2-adrenergic receptors activated alpha 2-adreno-
ceptor in the lateral hypothalamus, and this activation 
has anti-salivatory effects. Calcium channel blockers 
depress calcium influx due to inhibition of the voltage-
dependent calcium channels, thereby decreasing the 
acetylcholine-induced calcium elevation, and produce 
an inhibition of salivation (6). Angiotensin-converting 
enzyme inhibitors, alpha and beta-adrenergic blockers, 
and angiotensin II receptor antagonists are also related 
to xerostomia (26). In this study, we observed that hy-
pertensive HD patients have an increased risk of suf-
fering xerostomia vs. non-hypertensive HD patients. 
Nevertheless, we cannot compare our results with other 
papers because there are no studies about xerostomia in 
HD patients regarding the subject. 
Benzodiazepines decrease the salivary flow rate through 
the benzodiazepine receptors in the salivary glands and 
by indirect action on the salivary glands through the 
central benzodiazepine receptors (27). In this study, we 
observed an increased risk of dry mouth in HD patients 
taking benzodiazepines. As mentioned before, we have 
not found papers discussing HD patients.
There are studies that have evaluated the intensity of 
xerostomia in HD patients. Different subjective test and 
questionnaires have been used, VAS for thirst (only one 
item), VAS for xerostomia (only one item), dialysis thirst 
inventory and xerostomia inventory. Previous studies 
have shown a xerostomia inventory that ranges from 
20.6 to 33.1 in HD patients (1,11,19). The xerostomia 
inventory includes 11 items, each with a 5-points scale, 
the results range from 11 (no dry mouth) to 55 (extreme-
ly dry mouth) (15). We assessed the rate of xerostomia 
by VAS questionnaire, validated to evaluate the level of 
dry mouth (6,20). In our study, the mean VAS score of 
the HD patients was 31.74±14.88. Although xerostomia 
inventory and VAS values are no comparable, it seems 
that our results are lower than previously. 
In this study, we used the validated OHIP-14 question-
naire (21) to assess patient’s quality of life. We obtained 
a mean total OHIP-14 score of 24.38±11.98, and a posi-
tive correlation between VAS score and OHIP-14 score 
were observed in HD patients. Also, our mean OHIP-14 
scores were significantly higher in xerostomia patients. 
There are no previous studies that have evaluated OHIP-
14 in HD patients, but other authors (18) have used other 
quality of life questionnaires related to kidney disease 
like kidney disease quality of life (KDQOL). Fan et al. 
(18) observed that xerostomia is related to higher val-
ues of KDQOL. Our results cannot be compared with 
this study because the quality of life questionnaire was 
different, but we can conclude like Fan et al. (18) that 
xerostomia get worse the quality of life of HD patients. 
Therefore, treating xerostomia in HD patients could im-
prove their quality of life. 
There are studies (7,11,18,19) that have evaluated if 
xerostomia or thirst sensation were related to IDWG. 
Some studies have observed a significant positive cor-
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relation between xerostomia, thirst and IDWG (11,19), 
HD patients with high levels of thirst, and xerostomia 
gained more weight between HD sessions. However, 
there are papers (28) that have not found a significant 
correlation between IDWG and thirst intensity. In this 
study, we found a positive, non-significant correlation 
between IDWG% and total score of xerostomia VAS 
questionnaire, and a significant positive correlation be-
tween VAS level of thirst and IDWG%. We think, like 
other authors (11), that a thirst sensation produces a fre-
quent intake of fluids, HD patients could refuse to com-
ply with restrictions on fluids due to thirst sensation, 
which could enhance IDWG in HD patients. Overall, 
this problem could be very complex due to possible mul-
tifactorial aetiology and the physiology is not known. 
The sensation of xerostomia could be associated to hy-
posalivation, but this association is not always present 
(29). In our study, we only determined salivary flow in 
30 HD patients that received HD treatment first thing in 
the morning due to the influence of time measurement 
of saliva on the diagnosis of hyposalivation. The saliva 
test was performed at a fixed time-point of a limited 
time interval early morning due to the circadian rhythm 
of salivary flow (30). There are studies that showed that 
UWS flow rate varies between 0.4±0.3 and 0.45±0.25 
mL/min in older non-HD patients (9,29). The UWS 
mean of previous HD studies varies between 0.28±0.16 
and 0.31±0.28 mL/min (8,9,11,19). Our UWS mean 
(0.16±0.17) was lower than aforementioned reports.  
According to recent criteria, hyposalivation can be de-
fined as UWS rates below 0.1 mL per/min and SWS rates 
below 0.7 mL per/min (6,29), and appeared in 12.1% in 
the general population (29). Previous studies have found 
UWS hyposalivation in 28.8-40.5% of HD patients 
(11,18,19). In our study, hyposalivation was greater than 
previous general population and HD studies. We ob-
tained hyposalivation UWS and SWS values in 53.33% 
and 36.66% of HD patients, respectively. We found that 
57.1% of HD with UWS <0.1 mL/min and 33.3% of HD 
with SWS <0.7 mL/min had xerostomia; therefore, we 
have not found relationship between hyposalivation and 
xerostomia. We think that these discrepancies in mean 
UWS flow rate and hyposalivation prevalence could be 
due to different criteria to define hyposalivation (some-
times <0.15ml/min flow rate) and time of collection, is 
not specified in the previous papers, that we saw previ-
ously could influence in the quantity of salivary flow. 
In conclusion, xerostomia is a frequent problem in HD 
patients and it is related to many accumulative xerosto-
mia risks in these patients (ageing, systemic disorders, 
drugs, fluid intake restriction, and salivary parenchy-
mal fibrosis and atrophy). In this study, hypertension 
and benzodiacepine use was related to this problem. So, 
to treat xerostomia correctly in this group of patients, 
we have to take into consideration all potential fac-
tors related to dry mouth. It is not clear if xerostomia 
could influence the increase of IDWG. We believe that 
it is necessary to realize studies with a great number 
of HD patients to justify this possible relationship. In 
this study, we have confirmed that the hyposalivation 
it is not always present in xerostomia HD patients, thus 
could be an open door to associate xerostomia in HD 
patients to possible psychological problems.
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